Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3419657 | 0.91 | MEN1 (0.37) | ALDH1A1MEN1KMT2AL3MBTL1SMN1; SMN2 | |
| SCHEMBL3416475 | 0.89 | EPHX2 (0.38) | ALDH1A1MEN1KMT2AL3MBTL1SMN1; SMN2 | |
| SCHEMBL3419062 | 0.88 | MEN1 (0.37) | ALDH1A1MEN1KMT2AL3MBTL1SMN1; SMN2 | |
| SCHEMBL3418975 | 0.86 | MEN1 (0.36) | ALDH1A1MEN1KMT2AL3MBTL1SMN1; SMN2 | |
| SCHEMBL3418747 | 0.85 | MEN1 (0.35) | ALDH1A1MEN1KMT2AL3MBTL1SMN1; SMN2 | |
| SCHEMBL3420033 | 0.85 | ALDH1A1 (0.37) | ALDH1A1MEN1KMT2AL3MBTL1SMN1; SMN2 | |
| SCHEMBL3419925 | 0.84 | EPHX2 (0.36) | ALDH1A1MEN1KMT2AL3MBTL1SMN1; SMN2 | |
| SCHEMBL3421637 | 0.84 | EPHX2 (0.36) | ALDH1A1MEN1KMT2AL3MBTL1SMN1; SMN2 | |
| SCHEMBL3419498 | 0.84 | EPHX2 (0.36) | ALDH1A1MEN1KMT2AL3MBTL1SMN1; SMN2 | |
| SCHEMBL3422475 | 0.82 | ALDH1A1 (0.38) | ALDH1A1MEN1KMT2AL3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130712-A1 | ADAMANTANE DERIVATIVE, RESIN COMPOSITION USING THE SAME, AND RESIN CURED PRODUCT | IDEMITSU KOSAN CO., LTD. (JP) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130712-A1 | ADAMANTANE DERIVATIVE, RESIN COMPOSITION USING THE SAME, AND RESIN CURED PRODUCT | ARCN1, APP, ADAM17 | ALDH1A1 125/4885MEN1 3560/4885KMT2A 2786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.